News
Exact Sciences Stock Just Hit an All-Time High: Here's Why It Could Go Even Higher
In May, Andrew Left of Citron Research blasted Exact Sciences (NASDAQ: EXAS), calling the stock "a poster child for what goes wrong when Wall Street gets a hold of a healthcare concept with no....
3 Healthcare Value Stocks
When value investors search through 10-Ks and valuation ratios for stocks selling on the cheap, healthcare isn't typically a sector full of stocks selling at a deep discount. When those stocks go....
Why 2017 Could Be This Stock's Best Year Yet
Nearly five years ago, Abbott Labs spun off its biopharmaceutical unit into a separate entity. That new company, AbbVie (NYSE: ABBV), enjoyed a tremendous first year, with its share price soaring....
Why High-Flying Aurinia Pharmaceuticals Stock Could Still Be Dirt Cheap
If 2017 ended today, Aurinia Pharmaceuticals (NASDAQ: AUPH) would rank as one of the biggest winners of the year among biopharmaceutical stocks. Aurinia's share price has more than tripled so far....
2 Reasons Pfizer Is on Our Minds Today
In this Market Foolery podcast, and with the big news coming out of healthcare, host Chris Hill calls upon the expert insight of Industry Focus: Healthcare host Kristine Harjes.First, they....
A New FDA Approval Sends Small Cap Flexion Soaring
This week, small-cap biotech company Flexion (NASDAQ: FLXN) received its first FDA approval for Zilretta, a non-opioid sustained-release steroid injection for knee pain. In this week's episode of....
Why Do Companies Pay Dividends?
In this edition of Industry Focus, host Michael Douglass and Fool contributor Matt Frankel discuss dividends. They agree that dividends can be important features of a stock to income investors,....
Why Ardelyx Inc Skyrocketed Higher Today
Ardelyx (NASDAQ: ARDX) stock rose 44% on Thursday after the company announced positive data from the phase 3 T3MPO-2 trial testing its irritable bowel syndrome drug, tenapanor, after the close of....
Why AcelRx Pharmaceuticals Inc Got Cut in Half Today
AcelRx Pharmaceuticals (NASDAQ: ACRX) is down 57% at 12:41 p.m. EDT after the Food and Drug Administration rejected the company's pain medication Dsuvia. As I said earlier this month when the....
Should You Buy the Dip With MannKind Stock?
You knew it was coming. It was inevitable that MannKind (NASDAQ: MNKD) stock's red-hot momentum would come to an end. The biotech's share price more than tripled in less than two weeks. However,....
7 Essential Rules for Investing in Biotech Stocks
Successful investing boils down to minimizing risk while maximizing the potential for reward. That's true whether you're investing in stocks, bonds, cryptocurrencies, or anything else. But how you....
5 Game-Changing Cancer Drug Innovations Being Developed Right Now
Image source: Getty Images."The emperor of all maladies, the king of terrors." This phrase was used by a 19th century surgeon to describe cancer. More than a century later, the description....
How Safe Is AbbVie's Dividend?
The pharmaceutical industry has been a favorite among dividend investors, and AbbVie (NYSE: ABBV) has put together an impressive track record of treating its shareholders well. Dating back to....
Can Johnson & Johnson Really Start Growing Again?
It's hard to satisfy investors -- even a strong performance can just lead us to want more. Case in point: Johnson & Johnson (NYSE: JNJ). Though the healthcare giant's stock has posted a solid....
Why Snap, Seattle Genetics, and Pretium Resources Jumped Today
Wednesday was a generally good day for investors on Wall Street, featuring a gentle rise of about 0.15% to 0.25% for major benchmarks like the Dow and the S&P 500. The White House continued to....
Is Pfizer the Best Dividend Stock in Healthcare?
Pfizer Inc.'s (NYSE: PFE) sales have fallen sharply since its top-selling Lipitor lost patent protection back in 2012. However, steps management has taken to control costs and invest in cancer....
Is AbbVie the Best Dividend Stock in Healthcare?
AbbVie (NYSE: ABBV) is making headway toward diversifying itself away from its best-selling drug, Humira, but Humira still accounts for most of its sales and that makes buying AbbVie, because of....
Is Johnson & Johnson the Best Dividend Stock in Healthcare?
Johnson & Johnson (NYSE: JNJ) has increased the amount of money it returns to investors in the form of dividends every year for more than 50 years. Its diversification across various....
Here's Why Abeona Therapeutics Inc. Stock Spiked Today
Shares of Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biotech developing novel gene therapies to treat rare genetic disorders, popped as much as 14% higher on Wednesday morning after....
Is MannKind Corp Finally a Buy?
MannKind Corporation (NASDAQ: MNKD) shares are up over 175% this month, and that's got anyone who's been paying attention to this troubled biotech wondering, "Can I still buy?" The company's....
After Gaining 16% Early Last Week, This Marijuana Stock Quickly Kissed It All Goodbye
Few industries, if any, offer the type of growth that legal cannabis can bring to the table, which is a big reason why investors have flocked to marijuana stocks in droves. Many of the largest pot....
3 Reasons Why Pfizer Investors Will Win With a Consumer Business Sale or Spinoff
Nearly a year ago, reports surfaced that Pfizer (NYSE: PFE) was considering selling or spinning off its consumer healthcare business. But those were just reports. Nothing happened -- until now.On....
Mylan Deals a Blow to Teva Pharmaceutical
Generic drugmakers Mylan (NASDAQ: MYL) and Teva Pharmaceutical (NYSE: TEVA) usually deal blows to brand-name drug manufacturers, not each other, but that changed last week when the Food and Drug....
These Biotech Stocks Are Pricey, but Investors Can Still Buy Them
Sarepta Therapeutics (NASDAQ: SRPT) and Amicus Therapeutics (NASDAQ: FOLD) are two fast-growing biotech stocks that are trading at price-to-sales multiples north of 50, yet biotech investors may....
Amgen Wins Reprieve on Its 2nd-Best-Selling Drug
The "composition of matter" patent protecting Amgen Inc.'s (NASDAQ: AMGN) white-blood-cell-boosting drug Neulasta from competition has already expired. That may mean it's only a matter of time....